AstraZeneca investors will look past another strong set of quarterly results on Thursday to focus on the main issue ...

On supercomputers and life sciences, listening to Treasury naysayers risks letting work and political capital slip away ...

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended AstraZeneca's Imfinzi ...

A revival in AstraZeneca Plc shares faces a key test this week, with more likely to hinge on the drugmaker’s ability to ...

The green light from the European Medicines Agency is the first backing in the EU for the medicine, following its approval in ...

AstraZeneca (AZN.L, AZN) announced Imfinzi was recommended for approval in the European Union by CHMP as first and only immunotherapy ...

AstraZeneca PLC (LON:AZN), a leading global biopharmaceutical company with a market capitalization of $216.74 billion, has been making significant strides in the pharmaceutical industry, particularly ...

The Japanese pharma had one asset rejected by the FDA and withdrew a regulatory application for another, but already this ...

Imfinzi recommended for approval in the EU by CHMP as first and only immunotherapy for limited-stage small cell lung cancer Recommendation based on ADRIATIC Phase III trial results which ...

(Alliance News) - AstraZeneca PLC on Monday said Imfinzi has been recommended for approval in the EU as monotherapy for limited-stage small cell lung cancer.

Sanofi has announced that Rippon Ubhi has been appointed as the new Chair of the European Medicines Group (EMG). She will continue her role as Country Lead for Sanofi UK & Ireland alongside this new ...